SynthesisOral diseases2026
Interventions for Treating Actinic Cheilitis: A Systematic Review.
Synthesis in Oral diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundActinic cheilitis (AC) is a sun-related oral potentially malignant disorder with no established optimal treatment. This systematic review aimed to evaluate the therapeutic efficacy of available treatments for AC.
methodsRandomized Clinical Trials (RCTs) comparing AC treatments with placebo or other interventions were included. In February 2025, a literature search was conducted in PubMed, Cochrane Central, SciELO, ClinicalTrials.gov, Scopus, and Web of Science. Risk of bias was assessed using the RoB2 tool. A qualitative synthesis was performed for each clinical outcome.
resultsEight RCTs, involving 230 participants, were included. Treatments assessed included daylight or conventional photodynamic therapy (PDT) with or without methyl aminolevulinate (MAL), imiquimod, and CO
conclusionDue to limitations, the most effective AC treatment remains undetermined. Future research must improve methodology, assess standardized therapies, and include long-term follow-up to assess recurrences and malignant transformation.
trial registrationPROSPERO: CRD42024561899.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.